UPDATE: Jefferies & Company Reiterates Hold Rating, Lowers PT on Metabolix
In a report published Friday, Jefferies & Company reiterated its Hold rating on Metabolix (NASDAQ: MBLX), but slightly lowered its price target from $2.20 to $1.50.
Jefferies noted, “We expect the technology value of Metabolix's PHA IP to continue to be masked by uncertainty as to what economics it may be able to capture on manufacturing partnerships, as well as whether a step up in its cash burn will be required to move biochemical partnerships to commercialization. We reiterate our Hold rating.”
Metabolix closed on Thursday at $1.32.
Latest Ratings for MBLX
|Mar 2014||Ardour Capital||Downgrades||Accumulate||Hold|
|Nov 2012||Jefferies & Company||Maintains||Hold|
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.